Mikhail Blagosklonny, a leading researcher in aging and cancer, put forward a new conceptual framework that describes the various actors of aging. The theory stated that the aging is not caused by untargeted molecular damage. It is due to hypertrophy and hyperfunction – an unsuitable continuation to the growth developments, especially mTOR signaling. By the theory, mTOR that is acting as adaptive in the growth stages creates detrimental consequences and becomes a quasi-program in the adulthood in the later stages of people. This quasi-programs do not terminate during the adulthood, and ability to create an off-switch usually diminishes with age.It is also said that the molecular damages would still occur without considering the hyperfunction, but the theory states that the damage is irrelevant of aging. The new theory put forward by Blagosklonny is more appealing as conventional models such as molecular damage and oxidative stress theories have many identified deficiencies. The hyperfunction theory explains the aging as a casual chain starting from hypertrophy to various macroscopic pathologies and ultimately to death. Interestingly, Blagosklonny proposed the new theory of aging in a series of papers that started in the year 2006 and continued till 2011.
Blagosklonny further states that rapamycin is great in reducing the effects and aging and can significantly increase the healthy lifespan of the humans. The drug was isolated from a bacterium found in Easter Island in the year 1972 and initially used as an anti-fungal agent. The drug is useful in treating a number of diseases including cancer, coronary stent coating, tuberous sclerosis complex, hemolytic-uremic syndrome, systemic lupus erythematosus, and more. Dr. Blagosklonny conducts extensive research on its effects on aging and found that it can increase the longevity of a person significantly.He conducted tests on mice and showed that the aging mice get the ability to fight tuberculosis in a better way. The initial tests conducted on elder humans showed that they started showing immunological rejuvenation when administered rapamycin before any influenza vaccination.
Blagosklonny claims that the drug can add excellent overall health benefits in the later stages of human life by curing a number of diseases. Now, the scientists are in the process of verifying its overall effects and conducting tests on marmoset monkey. Various researches showed that rapamycin could also be used to treat Alzheimer’s disease as it reduced the brain lesions and prevented the cognitive issues in mice.Mikhail Blagosklonny is an oncology professor at Roswell Park Institute for Cancer located in New York. Before joining Roswell in 2009, he was working as a senior scientist at the Albany-based Ordway Research Institute. In the initial years of his career, Blagosklonny worked at New York Medical College as an associate professor. He secured his M.D. (internal medicine) and Ph.D. in cardiology and experimental medicine from First Pavlov State Medical University. Blagosklonny is collaborating with a number of science journals that are dedicated to both aging and cancer. He is the editor-in-chief of Oncotarget, Aging, and Cell Cycle and published more than 300 articles, book reviews, papers, and more.